Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06067477
Other study ID # FHMS 22-23 194 EGA
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2023
Est. completion date September 2025

Study information

Verified date May 2024
Source University of Surrey
Contact Abigail Bournot, PhD
Phone 01483689222
Email a.bournot@surrey.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to perform a double-blind, randomised, dose-response trial of vitamin D3 supplementation in United Kingdom (UK)-dwelling adults of white European, South Asian, and black African/Caribbean ethnicity to investigate the distribution of dietary intakes needed to maintain adequate vitamin D status in winter, as indicated by serum 25(OH)D concentrations at ranges of >25 to 50 nmol/L. In addition, this study will investigate the effect of vitamin D3 supplementation on immune health, muscular strength, and overall health.


Description:

The aim of this study is to perform a double-blind, randomised, dose-response trial of vitamin D3 supplementation in United Kingdom (UK)-dwelling adults of white European, South Asian, and black African/Caribbean ethnicity to investigate the distribution of dietary intakes needed to maintain adequate vitamin D status in winter, as indicated by serum 25(OH)D concentrations at ranges of >25 to 50 nmol/L. In addition, this study will investigate the effect of vitamin D3 supplementation on immune health, muscular strength, and overall health. Recruited participants will be randomised to take 400, 1000, or 2000 IU for 12 weeks. Fasting blood samples collected at baseline and 12 weeks will measure biochemical markers of vitamin D status (serum 25(OH)D, calcium, parathyroid hormone, albumin), lipid profile, ferritin, micronutrient status, and immune and inflammatory biomarkers. Muscular strength will be measured using sit-to-stand and grip strength tests. Questionnaires, food diaries, and dosimeters will be used to gather data on lifestyle, physical activity, dietary intake, and sun exposure.


Recruitment information / eligibility

Status Recruiting
Enrollment 114
Est. completion date September 2025
Est. primary completion date September 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - British white European, black African/Caribbean, or South Asian (self-reported) - Living in England for >2 months - Aged >18 years - No significant health issues - English or Urdu speaker Exclusion Criteria: - Medical condition or history which might impact study measurements (e.g., ischaemic heart disease, type 1 and type 2 diabetes, thyroid disease, osteoporosis, haematological disease, malignancy) - Medications known to affect vitamin D metabolism (i.e., hormone replacement therapy, anti-oestrogens treatment, antiepileptic drugs, and breast cancer treatment) - Pregnant or planning pregnancy during the study period - Regular use of sun beds - Having a sun holiday one month prior to commencing study or plans for a sun holiday within the study period. A sun holiday is generally defined as a holiday in a sunny resort outside of the UK. The researchers will assess this on a case-by-case basis depending on the time of year and expected weather conditions - Reported participation in another clinical trial occurring simultaneously - Previous intolerance or allergic reaction to vitamin D

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Vitamin D Supplement
Vitamin D Supplement

Locations

Country Name City State
United Kingdom Faculty of Health and Medical Sciences Guildford

Sponsors (2)

Lead Sponsor Collaborator
University of Surrey University of Reading

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Concentration of serum 25(OH)D (nmol/L) A blood sample will be analysed using liquid chromatography tandem mass spectroscopy (LC-MS). Dose-response change in serum 25(OH)D will be measured in nmol/L. Baseline and 12 weeks
Secondary Anthropometric measurements - weight (kg) Weight (kg) Baseline and 12 weeks
Secondary Anthropometric measurements - height (m) Height (m) Baseline and 12 weeks
Secondary Anthropometric measurements - height (cm) Height (cm) Baseline and 12 weeks
Secondary Anthropometric measurements - waist circumference (cm) Waist circumference measurement (cm) Baseline and 12 weeks
Secondary Anthropometric measurements - hip circumference (cm) Hip circumference measurement (cm) Baseline and 12 weeks
Secondary Concentration of serum calcium (nmol/L) Measure dose-response change in serum calcium measured in nmol/L Baseline and 12 weeks
Secondary Concentration of plasma parathyroid hormone (PTH) (pg/mL) Measure dose-response change in plasma parathyroid hormone (PTH) measured in pg/mL Baseline and 12 weeks
Secondary Concentration of serum albumin (g/L) Measure dose-response change in serum albumin measured in g/L Baseline and 12 weeks
Secondary Concentration of C-Reactive Protein (CRP) (mg/L) Measure dose-response change in CRP measured in mg/L Baseline and 12 weeks
Secondary Complete blood count Measure change in complete blood count Baseline and 12 weeks
Secondary Change in immune parameters Measure change in gene expression in white blood cells Baseline and 12 weeks
Secondary Number of participants with Acute Respiratory Tract Infections (ARTIs) Measure the frequency of ARTIs using a validated questionnaire 12 weeks
Secondary Muscular strength using a handgrip strength test (kg) Muscular strength measured using a dynamometer (measured to the nearest 0.1kg). The participant will squeeze the dynamometer with maximum effort for 5 seconds. Baseline and 12 weeks
Secondary Muscular strength and endurance using a sit-to-stand test Number of sit to stands in 30 seconds Baseline and 12 weeks
Secondary Blood analytes - micronutrient status Measure dose-response change in micronutrient status from blood samples Baseline and 12 weeks
Secondary Blood analytes - lipid profile (mg/dL) Measure change in lipid profile from blood samples measured in mg/dL Baseline and 12 weeks
Secondary Vitamin D consumption from diet Vitamin D intake will be measured through a 4-day food diary which participants will fill out for 4 day at home before and after the study. Baseline and 12 weeks
Secondary Physical activity questionnaire Assess level of physical activity using an International Physical Activity Questionnaire (short form) Baseline
Secondary Sun exposure behaviour questionnaire Measures amount of time spent in the sun (often, occasionally, never) and what parts of the body are exposed (head, hands, arms, legs, torso) over summer, spring, autumn and winter. Also questions any summer holidays abroad, in what month, what country was visited, number of hours of sun per day and what body parts were exposed (head, hands, arms, legs, torso) Baseline
Secondary Ultraviolet B radiation (UVB) sun exposure Sun exposure will be measured by a dosimeter, which measures UVB exposure. Participants wear this like a badge for 4 days before and after the study. Baseline and 12 weeks
Secondary Lifestyle questionnaire Measures:
- Skin type (Fitzpatrick scale)
Questions:
Questions what ethnicity they identify with, Holidays abroad, Education, Origin, Health, Pregnancy, Sun behaviours (what body parts are usually exposed to the sun, clothing, sun bathing, sunscreen use, sun bed use), Smoking, Drinking, Recreational drug use, Knowledge around vitamin D, supplement use, Milk, egg, oily fish and liver consumption
Baseline
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04244474 - Effect of Vitamin D Supplementation on Improvement of Pneumonic Children Phase 1/Phase 2
Recruiting NCT05459298 - ViDES Trial (Vitamin D Extra Supplementation) N/A
Completed NCT04476511 - The Efficacy and the Safety of Vitamin D3 30,000 IU for Loading Dose Schedules Phase 3
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT03920150 - Vitamin D 24'000 IU for Oral Intermittent Supplementation Phase 3
Completed NCT03264625 - The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis Phase 2
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT05506696 - Vitamin D Supplementation Study N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Completed NCT03234218 - Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
Completed NCT02906319 - Vitamin D and HbA1c Levels in Diabetic Patients With CKD N/A
Completed NCT02714361 - A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women N/A
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT02118129 - Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'. N/A
Not yet recruiting NCT01419821 - Vitamin D and Its Affect on Growth Rates and Bone Mineral Density Until Age 5 N/A
Completed NCT02275650 - The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter N/A
Completed NCT02187146 - The Effects of Serum Vitamin D and IVF Outcome N/A
Completed NCT01741181 - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 Phase 4
Completed NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency Phase 3